^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cabometyx (cabozantinib tablet)

    i
    Other names: XL184 tablet, BMS-907351 tablet, XL-184, BMS907351, BMS 907351, XL184, XL 184
    Company:
    Exelixis, Ipsen, Royalty, Takeda
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    1d
    Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis. (PubMed, Cancer Immunol Immunother)
    The combination of cabozantinib and atezolizumab has an acceptable safety profile and moderate antitumor activity as a second-line treatment for patients with R/M ESCC.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet)
    5d
    Novel Efferocytosis-Related Prognostic Signature for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization. (PubMed, Gut Liver)
    Additionally, the high-risk group showed higher sensitivity to four drugs, with CD14 expression negatively correlated with sensitivity to vandetanib and cabozantinib. This study developed a model based on efferocytosis-associated characteristics to predict the prognosis of HCC patients and those undergoing TACE treatment, thereby facilitating the formulation of personalized treatment plans.
    Journal
    |
    CD14 (CD14 Molecule) • NDUFA2 (NADH:Ubiquinone Oxidoreductase Subunit A2)
    |
    Cabometyx (cabozantinib tablet) • Caprelsa (vandetanib)
    6d
    Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Emory University | Trial completion date: Mar 2026 --> Dec 2026
    Trial completion date
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    7d
    CABOTHYROID: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. (clinicaltrials.gov)
    P2, N=41, Completed, Grupo Espanol de Tumores Neuroendocrinos | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    sunitinib • Cabometyx (cabozantinib tablet)
    10d
    Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=4, Terminated, Weill Medical College of Cornell University | Completed --> Terminated; Low accrual
    Trial termination
    |
    FLT3 (Fms-related tyrosine kinase 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4)
    |
    Cabometyx (cabozantinib tablet)
    10d
    Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=96, Active, not recruiting, City of Hope Medical Center | N=72 --> 96
    Enrollment change
    |
    temozolomide • Cabometyx (cabozantinib tablet)
    12d
    Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov)
    P1, N=32, Recruiting, Emory University | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Padcev (enfortumab vedotin-ejfv)
    13d
    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion
    |
    erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    14d
    Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study (clinicaltrials.gov)
    P2, N=54, Recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet)
    15d
    Systematic Management of a Critical CYP3A4 Interaction Between Cabozantinib and Carbamazepine: A Case Report of a Clinically Relevant Pharmacokinetic Interaction. (PubMed, Clin Case Rep)
    This was the case of a 62-year-old patient treated with cabozantinib and nivolumab for metastatic clear cell renal cell carcinoma, in whom a clinically significant pharmacokinetic interaction with carbamazepine was observed...This optimization was accompanied by a significant clinical improvement and radiological tumor control. This case has led to the ongoing need for a medication review before initiating this type of cancer treatment and the implementation of pharmacokinetic monitoring when an interaction was detected.
    PK/PD data • Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
    17d
    Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy (clinicaltrials.gov)
    P1, N=15, Completed, University of California, Irvine | Active, not recruiting --> Completed
    Trial completion
    |
    RAS wild-type
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Lonsurf (trifluridine/tipiracil)
    17d
    MegaMOST: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (clinicaltrials.gov)
    P2, N=455, Recruiting, Centre Leon Berard | Trial completion date: Nov 2026 --> Oct 2027 | Trial primary completion date: Feb 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • FLT3 (Fms-related tyrosine kinase 3) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • AXL (AXL Receptor Tyrosine Kinase) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SMAD4 (SMAD family member 4) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • FLT1 (Fms-related tyrosine kinase 1) • CDK6 (Cyclin-dependent kinase 6) • CCND3 (Cyclin D3) • TYRO3 (TYRO3 Protein Tyrosine Kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • NRAS mutation • BRAF V600 • KIT mutation • CDKN2A deletion • HRAS mutation • KRAS G12 • PDGFRA mutation • KRAS amplification • NRAS G12
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)